1.44
+0.02(+1.41%)
Currency In USD
Address
645 Summer Street
Boston, MA 02210
United States of America
Phone
857 273 8343
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
March 26, 2021
| Name | Title | Pay | Year Born |
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer & Director | 810,694 | 1971 |
| Dr. Jotin Marango M.D., Ph.D. | Chief Financial Officer & Head of Corporate Development | 577,120 | 1980 |
| Mr. Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations | 0 | N/A |
| Mr. David Damphousse M.S. | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Development Officer | 0 | 1970 |
| Dr. Caroline Germa M.D., Ph.D. | Chief Medical Officer | 0 | 1972 |
| Ms. Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy & Communication | 0 | N/A |
| Mr. Bob Lally | Senior Vice President of Finance & Operations | 0 | N/A |
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.